Southern Shuanglin Bio-Pharmacy addresses stock volatility, expands drug trials

Southern Shuanglin Bio-Pharmacy (SZSE: 000403) has issued announcements addressing recent stock trading volatility and progress in clinical trials for its immunoglobulin product. The company acknowledged a one-day trading anomaly where share prices deviated by 20.79% on April 7, 2025, but assured investors that internal operations are normal, with no undisclosed material information or pending significant events. The company's board confirmed it is unaware of any undisclosed matters that should have been disclosed.